What is GILD stock price today?

GILD (Gilead Sciences Inc) stock is trading at $148.95 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GILD stock going up or down today?

GILD stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GILD stock now?

The decision to buy GILD depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GILD a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GILD based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GILD stock overvalued or undervalued?

GILD currently trades at a P/E ratio of 21.97 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if GILD is fairly priced.

What is GILD's P/E ratio?

GILD has a price-to-earnings (P/E) ratio of 21.97, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is GILD's market cap?

GILD (Gilead Sciences Inc) has a market capitalization of $184.91 billion, making it a mid-cap stock.

What is GILD's price to book ratio?

GILD trades at a price-to-book (P/B) ratio of 8.15, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GILD pay dividends?

Yes, GILD pays dividends with a current yield of 0.02%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is GILD's dividend yield?

GILD's dividend yield is 0.02%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is GILD stock a good long-term investment?

GILD's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GILD's revenue growth rate?

GILD has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, GILD is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in GILD?

Key risks for GILD include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GILD compare to its competitors?

Compare GILD to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GILD's performance and positioning.

What is GILD's stock price target for 2026?

Our AI model provides price targets for GILD based on fundamental analysis: Bull case $193.63 (+30%), Base case $171.29 (+15%), Bear case $134.06 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GILD?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GILD. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GILD's next earnings report?

GILD reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GILD - Gilead Sciences Inc

NYSE * Health Care * Pharmaceuticals

$148.95

+$5.18 (+3.60%)

About Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

GILD Key Statistics

Market Cap

$184.91B

P/E Ratio

21.97

P/B Ratio

8.15

EPS

$6.78

Dividend Yield

0.02%

Revenue Growth

+0.0%

Profit Margin

0.3%

Employees

17,000

How GILD Compares to Peers

GILD has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

GILD has the highest profit margins in Pharmaceuticals

GILD is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
GILD(This stock)	$184.91B	22.0	0%	0.3%	-
AMZNAmazon Com	$2.25T	29.3	0%	0.1%	vs AMZN

Gilead Sciences Inc Company Information

Headquarters: California; U.S.A
Website: www.gilead.com
Sector: Health Care
Industry: Pharmaceuticals

GILD - Gilead Sciences Inc

About Gilead Sciences Inc

GILD Key Statistics

How GILD Compares to Peers

Gilead Sciences Inc Company Information

GILD Lician Score

GILD Financial Snowflake

Upcoming Events for GILD